iPierian Harvard Case Solution & Analysis

The iPierian case profiles a startup biotechnology company leveraging the recent development of induced pluripotent stem cells (iPSCs)-adult stem cells that have been reprogrammed to a "pluripotent" state whereby they can differentiate into around 200 distinct cell types in the body. The science in this area is in the nascent stages, but the pace of change is rapid as new discoveries are made and as companies formulate programs for the technology.

By creating a consistent strategy to make high quantities of high quality iPSCs and afterwards identify those cells into motor neurons iPierian has established itself as an early leader in the space. The company must decide between three important directions-tools, drug development of therapeutics-in which it remains to develop its technology and can steer the business. IPierian must also make this selection in the context of the role of big pharmaceutical players in the sector with whom they can either associate or possibly compete against in the race to discover programs that are successful for iPSC technology.

PUBLICATION DATE: February 04, 2011 PRODUCT #: E393-HCB-ENG

This is just an excerpt. This case is about STRATEGY & EXECUTION

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.